Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study

Publié en janvier 2019 JOURNAL OF INVESTIGATIVE DERMATOLOGY

Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

JOURNAL OF INVESTIGATIVE DERMATOLOGY

Publication précédente

Role of quantitative computed tomography in patients with severe precapillary pulmonary hypertension

JOURNAL OF INVESTIGATIVE DERMATOLOGY

Publication suivante